Display options
Cite
Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016;95(44):e5195doi: 10.1097/MD.0000000000005195.
Jawa, Z., Perez, R. M., Garlie, L., Singh, M., Qamar, R., Khandheria, B. K., Jahangir, A., & Shi, Y. (2016). Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine, 95(44), e5195. https://doi.org/10.1097/MD.0000000000005195
Jawa, Zeeshan, et al. "Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis." Medicine vol. 95,44 (2016): e5195. doi: https://doi.org/10.1097/MD.0000000000005195
Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195. PMID: 27858859; PMCID: PMC5591107.
Copy Download .nbib Format: NLM
Share it on

Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195.

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.

Medicine

Zeeshan Jawa, Ruth M Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K Khandheria, Arshad Jahangir, Yang Shi

Affiliations

  1. Department of Internal Medicine, Medical College of Wisconsin Aurora Research Institute, Aurora Health Care Department of Medical Oncology, Aurora Health Care Aurora Cardiovascular Services, Aurora Health Care Sheikh Khalifa bin Hamad Al Thani Center for Integrative Research on Cardiovascular Aging, Aurora Health Care, Milwaukee, WI.

PMID: 27858859 PMCID: PMC5591107 DOI: 10.1097/MD.0000000000005195

Abstract

BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of patients treated with trastuzumab will develop heart failure and ∼10% will experience a reduction in left ventricular ejection fraction (LVEF), the patient risk factors associated with trastuzumab-induced cardiotoxicity (TIC) are unclear. This meta-analysis aims to consolidate previously published data to identify the risk factors most likely leading to TIC.

METHODS: A search of the MEDLINE literature database using the keywords trastuzumab/Herceptin, risk factors, outcomes, cardiac, cardiotoxicity, cardiomyopathy, LVEF, and chemotherapy was performed. Only prospective/retrospective human studies were included, with additional studies excluded if they reported baseline LVEF > 68%, a cohort of <50 patients, or results that were not stratified based on cardiotoxic events. Pooled odds ratio (OR) and 95% confidence interval (CI) for each potential risk factor were calculated, with heterogeneity of data and samples explored using random-effects modeling.

RESULTS: Data were collected from 17 articles, capturing 6527 patients. Hypertension (OR 1.61, 95% CI 1.14-2.26; P < 0.01), diabetes (OR 1.62; 95% CI 1.10-2.38; P < 0.02), previous anthracycline use (OR 2.14; 95% CI 1.17-3.92; P < 0.02), and older age (P = 0.013) were all shown to be associated with TIC.

CONCLUSION: Cardiac performance should be closely monitored in women treated with trastuzumab. Recognizing potential risk factors along with careful attention to symptoms/LVEF measurements could minimize the occurrence of TIC in this population.

References

  1. J Card Fail. 2009 Oct;15(8):651-7 - PubMed
  2. Oncologist. 2011;16(8):1144-53 - PubMed
  3. Contemp Oncol (Pozn). 2013;17(2):190-5 - PubMed
  4. J Clin Oncol. 2008 Aug 1;26(22):3777-84 - PubMed
  5. Breast Cancer Res Treat. 2013 Nov;142(1):1-7 - PubMed
  6. BMC Cancer. 2007 Aug 08;7:153 - PubMed
  7. J Clin Oncol. 2012 Nov 1;30(31):3792-9 - PubMed
  8. Clin Transl Oncol. 2017 Jan;19(1):91-104 - PubMed
  9. Heart. 2013 May;99(9):634-9 - PubMed
  10. Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603 - PubMed
  11. Mayo Clin Proc. 2008 Feb;83(2):197-203 - PubMed
  12. J Clin Oncol. 2006 Sep 1;24(25):4107-15 - PubMed
  13. Nurse Pract. 2014 Feb 15;39(2):42-7 - PubMed
  14. JACC Heart Fail. 2015 Dec;3(12):956-64 - PubMed
  15. Breast Cancer Res Treat. 2011 Dec;130(3):845-54 - PubMed
  16. Arq Bras Cardiol. 2013 Apr;100(4):328-32 - PubMed
  17. J Am Coll Cardiol. 2007 Oct 9;50(15):1435-41 - PubMed
  18. J Clin Oncol. 2015 Jul 1;33(19):2176-83 - PubMed
  19. Oncologist. 2006;11 Suppl 1:4-12 - PubMed
  20. Ann Oncol. 2012 Apr;23(4):897-902 - PubMed
  21. J Card Fail. 2012 Feb;18(2):113-9 - PubMed
  22. J Clin Oncol. 2005 Nov 1;23(31):7811-9 - PubMed
  23. J Clin Oncol. 2013 Nov 20;31(33):4222-8 - PubMed
  24. J Clin Oncol. 2007 Sep 1;25(25):3859-65 - PubMed
  25. J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6 - PubMed
  26. Clin Cancer Res. 2011 May 15;17(10):3490-9 - PubMed
  27. Oncology. 2014;86(1):16-21 - PubMed
  28. Intern Emerg Med. 2012 Oct;7(5):439-46 - PubMed
  29. J Clin Oncol. 2003 Nov 1;21(21):3965-71 - PubMed
  30. Br J Cancer. 2012 Jan 3;106(1):6-13 - PubMed
  31. Anticancer Res. 2013 Apr;33(4):1717-20 - PubMed
  32. N Engl J Med. 2007 Jul 5;357(1):39-51 - PubMed
  33. Nat Rev Cardiol. 2010 Oct;7(10):564-75 - PubMed
  34. J Clin Oncol. 2002 Mar 1;20(5):1215-21 - PubMed
  35. J Am Soc Echocardiogr. 2014 Sep;27(9):911-39 - PubMed
  36. J Clin Oncol. 2005 Oct 20;23(30):7685-96 - PubMed
  37. Breast Cancer Res Treat. 2009 Sep;117(2):357-64 - PubMed
  38. Magy Onkol. 2006;50(4):293-302 - PubMed
  39. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  40. J Clin Oncol. 2010 Sep 1;28(25):3910-6 - PubMed
  41. Cancer. 2014 Jul 1;120(13):1932-8 - PubMed
  42. Breast Cancer Res Treat. 2012 Jul;134(1):291-8 - PubMed
  43. J Am Soc Echocardiogr. 2013 May;26(5):493-8 - PubMed

Substances

MeSH terms

Publication Types